NCT04720716 2026-03-19
A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
Clinical Trials
9 trialsNCT07455617 2026-03-06
Study of ABO2102 in KRAS-Mutated Solid Tumors
Suzhou Abogen Biosciences Co., Ltd.
Phase 1 Not yet recruiting
NCT06530251 2026-03-04
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
Akeso
Phase 1/2 Recruiting
NCT07005336 2026-01-30
A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer
TJ Biopharma Co., Ltd.
Phase 2 Active not recruiting
NCT06220318 2025-11-28
Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors
Fujian Haixi Pharmaceuticals Co., Ltd.
Phase 1/2 Active not recruiting
NCT05383482 2025-11-17
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
Laekna Limited
Phase 1/2 Completed
NCT05718219 2025-08-13
Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0348 in Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Active not recruiting
NCT05116462 2025-06-26
Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Active not recruiting
NCT03903705 2025-04-06
: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors
Hutchmed
Phase 1/2 Completed